Search results
1 lut 2022 · The BCL-6 test is a new test that can help clinicians identify patients with possible endometriosis or potential infertility. What is BCL-6 and its role in endometriosis? Researchers identified BCL-6 (B-cell lymphoma 6) as an oncogene or a gene that may affect the development of cancer.
ReceptivaDx is the only test that can identify endometriosis, progesterone resistance, and endometritis in a single sample. ReceptivaDx includes BCL6, a marker that identifies uterine inflammation most often associated with asymptomatic (silent) endometriosis.
ReceptivaDx includes BCL6, a marker that identifies uterine lining inflammation most often associated with asymptomatic (silent) endometriosis. BCL6 is found in more than 50% of women with unexplained infertility and around 65% of women with two or more IVF failures.
31 maj 2024 · BCL6 is the primary biomarker in the ReceptivaDx test for detection of endometriosis. This protein is an “oncogene” associated with lymphoma and involved with inflammation.
14 maj 2024 · The primary component in the ReceptivaDx™ test profile is BCL6 – a protein biomarker associated with inflammation. BCL6 is dramatically over-expressed in women with endometriosis, the most likely inflammatory condition causing unexplained infertility, recurrent miscarriage, and implantation issues.
An endometriosis screening test called ReceptivaDx TM (CiceroDx, Huntington Beach, CA) has been developed to detect endometrial BCL-6 overexpression in asymptomatic women with unexplained infertility or recurrent pregnancy loss. 2 It also detects beta-3 integrin expression, a cell adhesion molecule needed for successful implantation. 14,22,25 ...
Objective: To evaluate endometrial BCL6 expression as a prognostic biomarker for IVF outcome in women with unexplained infertility (UI) before ET. Design: Prospective cohort study. Setting: University-associated infertility clinic. Patient(s): Women with UI for >1 year.
